Analysis of the data obtained enabled recommendations for the maximum number of unplanned machine transfer fractions to be suggested. Outcome-based options for each site were given to clinicians for consideration. Table 1 shows the outcome based options for transfer number.
VMAT prostate (60 Gy, 20#), VMAT prostate with pelvic nodes (74 Gy, 37#) and conformal breast (40.05Gy, 15#) treatment sites have been analysed so far.
Each linac is able to deliver a treatment planned for the other linac.
ArcCheck results show no significant difference in gamma results for plans delivered on either type of linac signifying no significant difference in delivery performance.
Transferring plans from TB to iX resulted in approximately 2% higher dose for both VMAT and conformal plans with corresponding increase in dose to OAR.
The limiting factor for breast transfers was the volume receiving 107% of the prescription.
The limiting factor for prostate and prostate-nodes treatments was the dose to rectum and non-rectal bowel.
Transferring plans from iX to TB resulted in approximately 2% cooler dose for both VMAT and conformal plans. The limiting factor in all cases was the PTV coverage.